Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide
Hormone Receptor-Positive Breast Cancer
Explore 112 assets in Hormone Receptor-Positive Breast Cancer →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Tang-Du Hospital
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07618923CT.gov Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07317778CT.gov Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07383818CT.gov Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) | — | Recruiting | — | — | — |
NCT07307287CT.gov SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study | — | Not Yet Recruiting | — | — | — |
NCT06340230CT.gov SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hormone Receptor-Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide (this asset) | Tang-Du Hospital | P2 | CCC · 53 |
| Exemestane | Fujian Cancer Hospital | P4 | BBB |
| Everolimus | Ellipses Pharma | P4 | BBB |
| Anastrozole | University of Illinois at Chicago | P4 | BBB |
| Palbociclib | BeOne Medicines | P3 | BBB |
| Ribociclib | BeOne Medicines | P4 | BBB |
| Capecitabine | Kristina A. Fanucci | P4 | BBB |
| Abemaciclib | BeOne Medicines | P4 | BBB |
| Trastuzumab | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
+42 more in the Hormone Receptor-Positive Breast Cancer cohort
Other indications for Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 67 |
| Colorectal Cancer | — | P3 | BB · 66 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide in Hormone Receptor-Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-epidermal-growth-factor-receptor-her2-human-mus-musculus-monoclonal-shr-1805-1-chain-complex-with-human-mus-musculus-monoclonal-shr-1805-chain-dimer-thioether-with-n-6-3-mercapto-25-dioxo-1-pyrrolidinyl-1-oxohexylglycylglycyl-l-phenylalanyl-n-1r-1-cyclopropyl-2-1s9s-9-ethyl-5-fluoro-239101315-hexahydro-9-hydroxy-4-methyl-1013-dioxo-1h12h-benzodepyrano3467indolizino12-bquinolin-1-ylamino-2-oxoethoxymethylglycinamide-hormone-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →